Overview: Growth Hormone Suppression Panel
Introduction: The Growth Hormone Suppression Panel is a diagnostic tool designed to assess growth hormone suppression using serum samples. In India, GH suppression testing (oral glucose tolerance test) is essential for diagnosing acromegaly/gigantism (~3-4 cases per million annually), where failure to suppress GH (<1 ng/mL) after glucose load indicates autonomous secretion from pituitary adenoma. High morbidity from under-testing in rural/low-SES patients with enlarged extremities, coarse features, or excessive growth, limited endocrine labs, delayed somatostatin analogs/surgery leading to diabetes, hypertension, or cardiomyopathy. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs immunoassay for basal GH and post-glucose GH levels (multiple time points) over 1-2 days with high accuracy, valuable for confirming acromegaly in patients with clinical suspicion. This diagnostic falls under hormonal screening and targets adults/children with acromegaly features or high IGF-1, addressing accurate detection to guide medical/surgical therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise GH axis evaluation and reducing acromegaly complications. Its serum-based approach ensures reliable dynamic suppression assessment.
Other Names: GH Supp Pnl.
FDA Status: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.
Historical Milestone: GH suppression standard; in India, used in pituitary clinics.
Purpose: The test assesses 3 parameters including basal GH to guide growth hormone suppression evaluation, confirm autonomous secretion, inform therapy.
Test Parameters: 1. Basal GH, 2â€"3. Post-Glucose GH Levels (2 Time Points).
Pretest Condition: Fasting 10-12 hours required; patients should have suspected acromegaly.
Specimen: 3 mL serum in 1 SST (multiple timed draws), transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on acral enlargement, headache, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of glucose load (hypoglycemia in rare cases), benefits of confirming acromegaly, and minimal discomfort from multiple venipunctures.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret GH suppression within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols. Glucose load is administered under supervision.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or glucose intolerance can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Failure to suppress GH confirms acromegaly, necessitating specialist input. Normal suppression may require follow-up.
Specialist Consultation: Endocrinologists should be consulted for management.
Additional Supporting Tests: IGF-1, pituitary MRI for confirmation.
Test Limitations: Requires glucose tolerance; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Pituitary Studies India 2023.
